

1 **Title:** Uncovering Lasonolide A biosynthesis using genome-resolved metagenomics

2 **Running title (54 characters):** Elucidation of Lasonolide A biosynthesis

3 **Authors:** Siddharth Uppal^a, Jackie L. Metz^b, René K.M. Xavier^b, Keshav Nepal^b, Dongbo Xu^b,
4 Guojun Wang^{b*}, Jason C. Kwan^{a*}

5 **Affiliation:** ^aDivision of Pharmaceutical Sciences, School of Pharmacy, University of
6 Wisconsin—Madison, Madison, Wisconsin, USA

7 ^bHarbor Branch Oceanographic Institute, Florida Atlantic University, Florida, USA

8 *Address correspondence to Guojun Wang, guojunwang@fau.edu; Jason C. Kwan,
9 jason.kwan@wisc.edu

10 **Abstract**

11 Invertebrates, in particular sponges, have been a dominant source of new marine natural
12 products. For example, lasonolide A (LSA) is a potential anti-cancer molecule isolated from the
13 marine sponge *Forcepia* sp., with nanomolar growth inhibitory activity and a unique cytotoxicity
14 profile against the National Cancer Institute 60 cell line screen. Here, we identified the putative
15 biosynthetic pathway for LSA. Genomic binning of the *Forcepia* sponge metagenome revealed a
16 gram-negative bacterium belonging to the phylum Verrucomicrobia as the candidate producer of
17 LSA. Phylogenetic analysis showed this bacterium, herein named *Candidatus Thermopylae*
18 *lasonolidus*, only has 88.78% 16S rRNA identity with the closest relative *Pedosphaera parvula*
19 Ellin514, indicating it represents a new genus. The lasonolide A (*las*) biosynthetic gene cluster
20 (BGC) was identified as a *trans*-AT polyketide synthase (PKS) pathway. When compared with
21 its host genome, the *las* BGC exhibits a significantly different GC content and penta-nucleotide

22 frequency, suggesting a potential horizontal acquisition of the gene cluster. Furthermore, three
23 copies of the putative *las* pathway were identified in the candidate producer genome. Differences
24 between the three *las* repeats were observed including the presence of three insertions, two
25 single-nucleotide polymorphisms and the absence of a stand-alone acyl carrier protein in one of
26 the repeats. Even though the Verrucomicrobial producer shows signs of genome-reduction, its
27 genome size is still fairly large (about 5Mbp) and when compared to its closest free-living
28 relative contains most of the primary metabolic pathways, suggesting that it is in the early stages
29 of reduction.

30 **Importance**

31 While sponges are valuable sources of bioactive natural products, a majority of these compounds
32 are produced in small amounts by uncultured symbionts, hampering the study and clinical
33 development of these unique compounds. Lasonolide A (LSA), isolated from marine sponge
34 *Forcepia* sp., is a cytotoxic molecule active at nanomolar concentrations and causes premature
35 chromosome condensation, blebbing, cell contraction and loss of cell adhesion, indicating a
36 novel mechanism of action and making it a potential anti-cancer drug lead. However, its limited
37 supply hampers progression to clinical trials. We investigated the microbiome of *Forcepia* sp.
38 using culture-independent DNA sequencing to uncover how an uncultured bacterium produces
39 LSA. This provides future opportunities for heterologous expression and cultivation efforts that
40 may minimize LSA's supply problem.

41 **Keywords:** Lasonolide A, horizontal gene transfer, multiple repeats, Verrucomicrobia, *trans*-AT
42 PKS, genome reduction

43 **Introduction**

44 Lasonolide A (LSA) is a cytotoxic polyketide derived from the marine sponge *Forcepia* sp. (**Fig.**
45 **1A and 1B**) (1). Out of its analogs (B–G) (**Fig. 1C**), LSA is the most potent (2) and exhibits IC₅₀
46 values in the nanomolar range against certain cell lines in the National Cancer Institute 60 cell
47 line screen (3). Furthermore, its unique mechanism of action - induction of premature
48 chromosome condensation, loss of cell adhesion, activation of the RAF1 kinase in Ras pathway,
49 along with cell blebbing and contraction (3–5) - makes it a promising candidate as a scaffold for
50 future pharmaceutical development. However, a major challenge to its clinical development is
51 the lack of availability. Scarcity and limited accessibility of the sponge prevent it from being a
52 sustainable source of lasonolide A. Furthermore, the chemical synthesis of LSA is tedious and
53 has poor yields, limiting its scalability (6–8).

54 It is well known that bacteria living in a symbiotic relationship with higher animals are valuable
55 sources of novel bioactive secondary metabolites (9). In many instances, these molecules serve a
56 protective function for the host but the identity of the microbial producer remains unknown (9–
57 12). Furthermore, attempts to isolate these associated microbes are hampered by low cultivation
58 success; it is estimated less than 1% of bacteria are currently culturable from the environment
59 (13–15). These drawbacks have created the need to genetically engineer surrogate hosts for the
60 sustainable and sufficient production of the desired natural products in the laboratory. The first
61 step in engineering microbes for production of bioactive compounds is to identify the genes
62 responsible for natural product synthesis, which can be elucidated through metagenomic analysis
63 and cloning (16, 17). Based on its potent antitumor activity, it is likely that LSA also acts as a
64 chemical defense within its host sponge. The structure of LSA very likely arises from an
65 assembly-line type polyketide synthase (PKS), rather than the iterative PKSs that predominate in

66 fungi and other eukaryotes, and therefore the source is likely bacterial (18–20). Identifying the
67 bacterium responsible for synthesizing LSA and elucidating its biosynthetic pathway will allow
68 us to explore routes for LSA’s heterologous expression, and potentially facilitate the synthesis of
69 analogs.

70 Here, we describe a *trans*-AT PKS pathway (*las*) that is likely responsible for the biosynthesis of
71 LSA. Furthermore, the entire *las* BGC has been captured on five overlapping fosmid clones and
72 reassembled for the purpose of heterologous expression. We propose that the *las* BGC is present
73 in a yet uncultivated bacterium belonging to a novel genus under the phylum Verrucomicrobia.
74 Additionally, evidence suggests the *las* BGC is repeated thrice within the Verrucomicrobia
75 symbiont with minor sequence variations between them. We also suggest that the *las* BGC has
76 been horizontally acquired and has a codon adaptation index comparable to that of highly
77 expressed genes. Finally, we show that the Verrucomicrobia symbiont is in very early stages of
78 genome reduction and is likely to further reduce its size.

79 **Results and discussion**

80 Identification and capture of *las* BGC

81 In our initial studies, we constructed a high-capacity metagenomic DNA library consisting of
82 ~600,000 *cfu* from *Forcepia* sp. sponges collected from the Gulf of Mexico (**Fig. 2A**) to search
83 for potential *las* biosynthetic genes. The structure of LSA contains two tetrahydropyran rings and
84 two β -methylations (21, 22) at C-13 and C-35 (**Fig. 2B**). These structural features have been
85 identified in a variety of *trans*-AT PKS pathways but are rarely found in *cis*-AT PKS systems
86 (23, 24) thus hinting that LSA is produced by a *trans*-AT PKS pathway (24). Therefore, clade-

87 guided degenerate primers targeted to conserved *trans*-AT PKS genes such as 3-hydroxy-3-
88 methylglutaryl-CoA (HMG-CoA) synthase, free-standing ketosynthase (KS), acyl carrier protein
89 (ACP), and two enoyl-CoA hydratases (ECH) were utilized for initial screening of the *Forcepia*
90 fosmid library (**Table S1A**). From the metagenomic library, five fosmids were identified using
91 these primers (fosmids 5-16, 6-71, 3-46, 1-80, and 4-77) resulting in the capture of
92 approximately 48kb of the putative *las* BGC at its 3' end (**Fig. S1A**). However, minimal progress
93 was made toward capturing the remaining half of the BGC as primer walking failed to produce
94 new hits in the region upstream of fosmid 5-16. Therefore, we sequenced the metagenome of
95 *Forcepia* sp. and searched for *trans*-AT PKS BGCs. DNA was extracted from two different
96 regions (referred to as *Forcepia_v1* and *Forcepia_v2*) of the same sponge, and subjected to whole
97 genome shotgun metagenomic sequencing. The reads were trimmed, assembled and then binned
98 into metagenome assembled genomes (MAGs). The metagenomes were found to be abundant in
99 Acidobacteria, Proteobacteria and Chloroflexota (**Fig. 2C and S1B**), with 56 and 55 MAGs
100 recovered from the two metagenomes. Based on MiMAG (25) standards for completeness and
101 contamination, 11 and 6 MAGs were high quality and 21 and 19 MAGs were medium quality,
102 for *Forcepia_v1* and *Forcepia_v2*, respectively (**Table S2**).

103 A tBLASTN (26) search of KS domains from publicly available *trans*-AT PKS pathways against
104 our assembled metagenome was performed. In the case of *Forcepia_v1*, the top hits were all to a
105 contig of length 98kbp labeled *gnl|UoN|bin5_1_edit_8*, thus strongly suggesting that this contig
106 contains *trans*-AT PKS genes and may possess the potential LSA pathway. Contig
107 *gnl|UoN|bin5_1_edit_8* was manually inspected and corrected for sequence gaps (**Text S1**). With
108 the exception of a 1.1kbp contig annotated as containing a *trans*-AT PKS pathway with a
109 truncated condensation domain (in *bin3674_131*), analysis of the metagenome using

110 AntiSMASH (27) (**Fig. 2D**) did not reveal any other BGC with plausible size and genes for the
111 synthesis of LSA. Contig gnl|UoN|bin5_1_edit_128 (3.6 kbp) which was connected to the 5'
112 end of gnl|UoN|bin5_1_edit_8 was found to contain a stand-alone ACP domain and about 47
113 amino acid residues which completed the terminal KS domain of gnl|UoN|bin5_1_edit_8 (see
114 multiple repeats of the *las* BGC). Both the contigs were assembled together and annotation of
115 genes and biosynthetic domains within this assembly re-affirmed that they are likely involved in
116 LSA synthesis. We termed the gene cluster deemed relevant to LSA biosynthesis as *las* BGC_v1.
117 Furthermore, the sequence of *las* BGC_v1 was also in alignment with fosmids identified from
118 the metagenomic library. A screening strategy was then developed for isolating the previously
119 missing 5' end of the pathway from the metagenomic library (fosmids 5-41, 2-18 and 2-13) (**Fig.**
120 **S1A and Table S1B**).

121 Inspection of the MAGs revealed that gnl|UoN|bin5_1_edit_8 binned with genome bin75_1.
122 However, to our surprise, visual inspection of the assembly graph (**Fig. S1C**) in BANDAGE (29)
123 indicated that gnl|UoN|bin5_1_edit_8 is present between contigs belonging to bin5_1 (phylum
124 Verrucomicrobia). Furthermore, mapping the paired-end reads on the genomic bin (**Fig. S1D**)
125 showed that multiple read pairs aligned across the contig junction. The terminal connections
126 between contig gnl|UoN|bin5_1_edit_8 and several contigs in bin5_1 were verified via PCR
127 (**Table S1C**) and Sanger sequencing of the amplicons using metagenomic DNA as the template.
128 Based on this evidence gnl|UoN|bin5_1_edit_8 was manually placed with bin5_1, as well as
129 additional contigs (**Text S1**).

130 In the case of Forcepia_v2, tBLASTN of KS domains hit to eight different contigs which could
131 be assembled together (<https://www.geneious.com>) (**Fig. S1E**). Except for contig
132 gnl|UoN|bin4_1_edit_10 the other seven contigs assembled into a single large contig of 102kbp

133 (*las* BGC_v2). Similar to *las* BGC_v1, inspection of the assembly graph (**Fig. S1F**) and mapping
134 of paired-end reads (**Fig. S1G**) revealed that contigs forming *las* BGC_v2 have been binned
135 incorrectly and should be part of the bin4_1 (phylum Verrucomicrobia). As a result, the contigs
136 comprising *las* BGC_v2, as well as additional contigs (**Text S1**) were manually placed with
137 bin4_1. No other contig containing a *trans*-AT PKS pathway was identified in the metagenome
138 (**Fig. S1H**).

139 Alignment of *las* BGC from both Forcepia_v1 and Forcepia_v2 using clinker (28) revealed that
140 these pathways are highly similar (**Fig. 2E**). The amino acid identity is 100% for most of the
141 genes except for *lasJLO* where the amino acid identity is 98.37%, 99.84% and 99.83%
142 respectively. The slightly lower identity of *lasJLO* is due to the insertion sequence present in *las*
143 BGC_v2 but absent in *las* BGC_v1. These insertion variants were later identified to be present in
144 some repeats of *las* BGC_v1 as well.

145 The putative symbiont genome carrying the *las* BGC (Forcepia_v1 bin5_1 and Forcepia_v2
146 bin4_1) was identified to belong to phylum Verrucomicrobiota, order Pedosphaerales, and genus
147 UBA2970 by GTDB-TK v1.5.0 (database r202) (30). Excluding the *las* genes, the ANI of
148 Forcepia_v1 bin5_1 and Forcepia_v2 bin4_1 is 99.9%, suggesting little strain heterogeneity
149 between the sites in the sponge, beyond a small amount perhaps attributable to sequencing errors.
150 To our knowledge, this is the first time a *trans*-AT PKS BGC has been reported in an organism
151 belonging to order Pedosphaerales. A phylogenetic tree of 51 different Verrucomicrobia
152 genomes (**Fig. S1I**) placed the LSA producer in subdivision 3 (NCBI taxonomy). The closest
153 relative of the symbiont with a publicly available genome is *Pedosphaera parvula* Ellin514
154 (GCA_000172555.1), with 88.78% identity to the 16S ribosomal RNA sequence. As per the 16S
155 taxonomic cutoffs proposed by Yarza et al. (31), this represents a new genus within the family

156 AAA164-E04 (as classified by GTDB-Tk (30)). We named the bacterium “*Candidatus*
157 *Thermopylae lasonolidus*”: *Thermopylae* is a tribute to the 300 Spartan hoplites and other Greek
158 soldiers that fought at the battle of Thermopylae. The Spartans fought to protect Greece from
159 Persians and the LSA-producing bacterium with its three copies of the *las* BGC (see below) is
160 proposed to be protecting the host sponge from predators. *Lasonolidus* suggests the bacterium is
161 associated with lasonolide A and also rhymes with the Spartan king of the 300 hoplites,
162 Leonidas. Despite being the putative producer of LSA, “*Ca* *T. lasonolidus*” is not highly
163 abundant in the metagenome, having a relative abundance of just over 2.65% in *Forcepia_v1* and
164 1.78% in *Forcepia_v2* (**Fig. 2C and Fig. S1B**).

165 With the aid of metagenome sequence, additional fosmids covering the 5′-end were acquired
166 (Fig. S1), which enabled us to capture the *las* BGC minimally on 5 fosmids (Fig. 3) and to
167 subsequently reassemble the BGC into a plasmid for heterologous expression. Network analysis
168 with BiG-SCAPE (32) revealed no shared families with MIBiG reference BGCs indicating the
169 novelty of the *las* BGC.

170 Model for lasonolide biosynthesis by *las* BGC

171 The proposed biosynthetic scheme for the synthesis of LSA based on the *las* BGC is shown in
172 **Fig. 3**. The complete *las* BGC consists of six *trans*-AT PKS proteins (*lasHJLMNO*), ten
173 accessory genes (*lasCDEFIKPQRS*) and five genes with no or unknown role in LSA synthesis
174 (*lasABGTU*). Phylogenetic analysis of 944 different KS domains (**Fig. S2**) was used to predict
175 KS substrate specificity (33), which was found to be similar to the proposed biosynthetic model.
176 The pathway is predicted to be collinear with the first KS domain of *lasH* clustering into the
177 same clade as other starter KS domains in the KS phylogenetic tree. Moreover, the last *trans*-AT

178 PKS protein (*lasO*) contains a condensation domain, similar to those found in nonribosomal
179 peptide synthetase pathways, as its terminal domain, which is proposed to be responsible for
180 cyclizing and cleaving the final PKS product (24).

181 An acylhydrolase (AH) domain is often used in *trans*-AT PKS systems for proofreading by
182 cleaving the acyl units from stalled sites (34, 35). AHs are closely related to acyltransferase (AT)
183 domains, which are involved in the addition of malonyl-*S*-coenzyme A extender units on the
184 phosphopantetheine arms on ACP domains (24, 36). LasE (AH) and LasF (AT) were correctly
185 identified as AH and AT domains respectively, based on the presence of active site residues (**Fig.**
186 **S3A**) and phylogeny (35) (**Fig. S3B**). The accessory proteins LasCDRS include enzymes known
187 to be involved in β -branch formation at module 1 and 10 (21). The ACPs at module 1 and 10
188 contain a conserved tryptophan which is involved in interacting with β -branching enzymes (37,
189 38). LasR was identified to be responsible for dehydration (ECH1) while LasH ECHb and LasO
190 ECHb to be responsible for decarboxylation (ECH2) during β -formation (39) (**Fig. S3C**). Due to
191 their truncated size and lack of homology to the conserved sites needed for oxyanion hole
192 formation LasH ECHa and LasO ECHa are proposed to be inactive (40, 41) (**Fig. S3D and S3E**).
193 An endo- β -methyl (\square, β -unsaturated β -methyl) is predicted to form on module 10. The presence
194 of a truncated ECH domain just upstream of ECH2 domain has been commonly observed with
195 the formation of exo- β -methylene (β, γ -unsaturated β -methylene), but to our knowledge this is
196 the first time such an architecture has been reported to form a endo- β -methyl (38). Based on the
197 collinearity of the pathway suggested above and the split module architecture (KS-DH MOX
198 ACP-KS) associated with different Baeyer-Villiger (BV) monooxygenases as seen in oocydin
199 and sesbanimide biosynthesis (42–44) we propose LasI to be involved in BV oxidation and LasK
200 in the addition of a hydroxyl group. Based on the recent reports that the most common

201 transformation by cytochrome P450 enzymes in PKS biosynthesis is C-H hydroxylation (45) we
202 suggest LasP to be oxidizing C-31. Another accessory protein, the enoylreductase (ER) domain
203 LasQ (46) is proposed to be acting in *trans* as observed in other pathways including lagriamide
204 (47), patellazoles (48) and bacillaene (24, 49).

205 Due to the disruption of the catalytically active residues (CHH, **Fig. S3F**), we predict certain KS
206 domains to be inactive (LasL KS1, LasL KS4, LasM KS5 and LasO KS7). We propose that the
207 ACP domain of LasL directly takes the molecule from the first ACP of LasJ and thus we predict
208 the KS domain in LasJ to be catalytically inactive despite the presence of catalytic residues, as
209 observed in lagriamide, lankacidin, and etnangien pathways (24, 36). Likewise, the alignment of
210 ketoreductase (KR) domains (**Fig. S3G**) allowed us to identify the ones lacking the KSY
211 catalytic triad and thus spot the inactive KR domain in module 2 (LasL KR1). Additionally, it
212 was found that the predicted stereoconfiguration of KR products (50, 51) in the *las* BGC,
213 matched the configuration of the equivalent moieties within the LSA structure produced by total
214 synthesis (8). The absence of a KR domain required in module 14 is proposed to be compensated
215 by a *trans*-acting KR likely from the following module as proposed in the patellazole (48)
216 pathway.

217 We were able to identify two pyran synthase (PS) domains (in module 7 and module 13) based
218 on their phylogeny (**Fig. S4A**) and alignment (52, 53) (**Fig. S4B**). These PS domains are at the
219 correct position in the *las* BGC to insert the pyran rings required to synthesize LSA. Even
220 though module 13 lacks a DH domain required for pyran ring formation, we predict this role to
221 be played by a *trans*-acting DH domain as commonly seen in *trans*-AT PKS pathways (24).
222 Similarly, we were able to identify double bond-shifting DH domains in module 4 (LasM DH1)
223 and 8 (LasN DH1) by the absence of both proline at the HxxxGxxxxP motif and of Glutamine/

224 Histamine at the DxxQ/H (**Fig. S4C**) (54) motif. Moreover, alignment of the DH domains
225 allowed us to identify the presence of inactive DH domains in module 2 (LasH DH1) and 6
226 (LasM DH2) by the absence of catalytic histidine at the HxxxGxxxxP motif and catalytic
227 aspartic acid at the DxxxQ/H motif (**Fig. S4D**). LasL DH3 has a serine in place of proline in its
228 HxxxGxxxxP motif. Alignment with different DH domains with serine in the HxxxGxxxxP
229 motif revealed a mixture of domains annotated as active and inactive (**Fig. S4E**). The majority of
230 times, when the DH domain had the conserved histidine in the HxxxGxxxxP motif it was
231 annotated as active. Based on this we propose LasL DH3 to be active. Specific primers were
232 designed based on the *las* BGC sequence and used to identify additional fosmids so that the
233 whole pathway could be assembled from five overlapping clones for future heterologous
234 expression.

235 For the biosynthesis of other LSA analogs, we propose that all of them except for lasonolide D
236 are modified post PKS (**Fig. 4**). The cytochrome P450 LasP is predicted to oxidize LSA at C-37
237 and C-36 leading to the synthesis of lasonolide B and C respectively. However, in the complete
238 biosynthesis of lasonolide B it is unclear how the methyl group is transferred from C-38 in LSA
239 to C-36 in lasonolide B. Recently it was shown that serine hydrolase activity of lipid droplet-
240 associated hydrolase is responsible for cleaving the ester bond in LSA and yielding the active
241 form of the molecule, i.e. lasonolide F (55). Due to its hydrophobicity LSA is able to easily
242 diffuse into the plasma membrane and into lipid droplets, where it is converted into lasonolide F,
243 which is more hydrophilic and therefore able to diffuse out of the lipid droplet and into the
244 cytoplasm to exhibit its cytotoxic effect (55). Lasonolide C seems to undergo an esterification
245 reaction with a long-chain fatty acid ($\text{CH}_3(\text{CH}_2)_{10}\text{COOH}$) to produce lasonolide G. We suggest
246 that lasonolide E is also biosynthesized by a *trans*-esterification reaction, by reacting with an

247 ethanol molecule. As with the production of LSA, we suggest that for the biosynthesis of
248 lasonolide D the molecule passes through the entire *las* BGC, however, the starter molecule in
249 this case is an acetate instead of a malonate that gets loaded on the ACP of LasJ, with LasH and
250 LasI being inactive.

251 Multiple repeats of the *las* BGC

252 The k-mer coverage of the *las* BGC (400.165× for *las* BGC_v1 and 159.02× for *las* BGC_v2) is
253 roughly three times that of “*Ca. T. lasonolidus*” (135.16x in Forcepia_v1 and 48.24x in
254 Forcepia_v2). The 3× coverage suggests three repeats of the putative *las* BGC. Visual inspection
255 of the assembly graph as well as mapping of the paired-end reads onto “*Ca. T. lasonolidus*”
256 allowed us to identify three connections on the 3' end of *las* BGC but only two connections on
257 the 5' end of the pathway (contig 7 and 8) (**Fig. 5 and Table S3**). Another contig (contig 5) was
258 observed to be connected to *las* BGC about 3 kbp (3.6 kbp for *las* BGC_v1 and 3.7 kbp for *las*
259 BGC_v2) from the 5' end of *las* BGC. This suggests that the majority of *las* BGC (about
260 98kbp) is repeated thrice with a 3 kbp segment of the pathway (contig 6) is repeated twice (**Fig.**
261 **5**). The two repeats of contig 6 were further verified by more than twice paired end reads
262 mapping to it as compared to contig 5 (56) as well as its 2× coverage when compared to “*Ca. T.*
263 *lasonolidus*”. All the connections between the *las* BGC and the bacterial genome were verified
264 using PCR and Sanger sequencing of the amplicons. We believe that the three repeats of the *las*
265 BGC might be involved in contributing to the increased expression of LSA through increased
266 gene dosage (57).

267 On comparing the three repeats it was observed that the *las* BGC repeat connected to contig 5
268 lacks *lasC* (ACP domain, highlighted area in **Fig. 5**), which is predicted to play an important role

269 in β -branch formation. Furthermore, the same repeat which lacks *lasC* also shows the presence
270 of an incomplete *lasD* (decarboxylating KS domain used in β -branching). Although this KS
271 domain has the catalytic active site residues SHH, characteristic of decarboxylating KSs (38), it
272 lacks about 47 amino acids that are present in the KS domain of the other two repeats connected
273 to contig 6. On further investigation with GATK HaplotypeCaller (58, 59) we were able to detect
274 three insertions and two single nucleotide polymorphisms (SNPs) between the three repeats of
275 *las* BGC_v1 (**Fig. 6 and Table 1**). This was further supported by the allelic depth (AD) -
276 informative reads supporting each allele - and phred-scaled likelihoods (PL) of the possible
277 genotypes. The genotype quality (GQ) which represents the confidence in the PL values was 99
278 for all five variants, which is the maximum value GATK reports for GQ. Furthermore, alignment
279 of *las* BGC_v1 with *las* BGC_v2 revealed that *las* BGC_v2 contains all the variants that were
280 called by GATK, thus further supporting their presence. All the three insertions are multiples of
281 three base pairs (60bp, 24bp and 54bp), and are thus not causing any frame-shift mutations.
282 Moreover, all the three insertions lie between *trans*-AT PKS domains, suggesting they do not
283 contribute to functional differences. Change in one base from G to A at 93,995 bp does not result
284 in a change in the amino acid sequence as both codons (TAT and TAC) encode for tyrosine.
285 Finally, the change in base from A to G at 95,154 bp lies just outside *lasS*, i.e. in the non-coding
286 region. The above-mentioned differences in the three repeats of *las* BGC indicate that the repeats
287 have been present long enough to allow divergence. However, the differences between the three
288 repeats are not predicted to affect the function of the *las* BGC.

289 Evidence for horizontal gene transfer

290 During the binning process by Autometa (60), Barnes-Hut Stochastic Neighbor Embedding (BH-
291 tSNE) was used to reduce 5-mer frequencies to two dimensions. Generally, contigs belonging to
292 the same genome would have similar 5-mer frequency and would be expected to cluster close to
293 each other (61, 62). Visualization of the dimension-reduced data (**Fig. 7A–B and S5A–B**),
294 revealed that the *las* BGC contigs significantly differ in their 5-mer frequency from “*Ca. T.*
295 *lasonolidus*”, suggesting that the *las* BGC could have been recently horizontally acquired.
296 Furthermore, the GC% of the *las* BGC is significantly different ($p < 0.05$, ANOVA followed by
297 Tukey HSD) from annotated, hypothetical and pseudogenes (**Fig. 7C and S5C**) providing further
298 evidence for horizontal transfer of the *las* BGC.

299 Codon adaptation index (CAI) compares the synonymous codon usage of a gene and that of a
300 reference set along with measuring the synonymous codon usage bias (63). The CAI for the *las*
301 BGC was significantly different ($p < 0.05$, ANOVA followed by Tukey HSD) from the
302 annotated, hypothetical and pseudogenes, but matched that of highly expressed genes (i.e.
303 ribosomal proteins) (**Fig. S5D-E**). Thus, despite its horizontal acquisition, the BGC’s codon
304 usage has been adapted to be efficiently translated even though the 5-mer composition is still
305 different when compared to the rest of the “*Ca. T. lasonolidus*” genome.

306 The genome of the putative lasonolide producing symbiont

307 “*Ca. T. lasonolidus*”, with multiple *las* BGC repeats, represents an important addition to the
308 growing collection of symbiotic Verrucomicrobia (“*Candidatus Didemnitutus mandela*” and
309 “*Candidatus Synoicohabitans palmerolidicus*”) being identified with repeated *trans*-AT PKS

310 BGCs (57, 64, 65). Recently, two simultaneous studies have also identified a *trans*-AT PKS
311 BGC for pateamine in a bacterium (“*Candidatus* Patea custodiens”) belonging to phylum
312 Kiritimatiellaeota (66, 67), a recently proposed phylum which was previously classified within
313 Verrucomicrobia (68). This highlights the importance of this understudied phylum as an
314 important producer of natural products. “*Ca. T. lasonolidus*” is little over 5 Mbp long and has
315 GC percentage of about 53%. It is estimated to be 99% complete, is 1.35% contaminated (69),
316 has tRNAs for all amino acids and complete 5S, 16S and 23S rRNA genes. Based on MIMAG
317 standards (25) the bin is classified as a high-quality MAG. Detailed statistics of the putative LSA
318 producer are provided in **Table 2**.

319 Eukaryotic-like proteins (ELPs) are known to be present in genomes of sponge symbionts and
320 have been found to play an important role in regulating their interaction with the host sponge
321 (70–73). It is hypothesized that interaction with ELPs allow the symbiotic bacteria to evade
322 phagocytosis by the sponge, thus allowing discrimination between food and symbiont bacteria
323 (72, 74). A number of ELPs were identified in “*Ca. T. lasonolidus*” (**Table 3, and Table S4A**),
324 thus suggesting a symbiotic relationship of the bacterium with the *Forcepia* sp.

325 Bacterial microcompartments (BMCs) are organelles that enclose enzymes within a selectively
326 permeable proteinaceous shell (75), and they are rare among bacteria. Members of the phyla
327 Planctomycetes and Verrucomicrobia have a unique BMC gene cluster called the
328 Planctomycetes-Verrucomicrobia bacterial microcompartment (PV BMC) which is responsible
329 for production of microcompartment shell proteins BMC-P and BMC-H, as well as degradation
330 of L-rhamnose, L-fucose and fucoidans (71, 76, 77). Genes encoding the PV BMC cluster were
331 identified in “*Ca. T. lasonolidus*” (**Table S4B**), and the respective gene clusters in *Forcepia*_v1
332 “*Ca. T. lasonolidus*” and *Forcepia*_v2 “*Ca. T. lasonolidus*” were compared using clinker (28)

333 and were found to be 100% identical to each other. One interesting finding was that the
334 identified PV BMC clusters had a DNA-methyltransferase and PVUII endonuclease gene
335 between the first and the second BMC-H genes. This is different from the usual arrangement of
336 the PV BMC gene cluster where both the BMC-H genes lie next to each other and the cluster
337 lacks DNA-methyltransferase and PVUII endonuclease genes (**Fig. 8**). The presence of PV BMC
338 genes in the “*Ca. T. lasonolidus*” genome suggests that it possesses bacterial microcompartments
339 and that they might be involved in L-fucose and L-rhamnose degradation. Despite repeated
340 attempts, we only found rhamnulokinase and fumarylacetoacetate hydrolase family proteins in
341 the “*Ca. T. lasonolidus*” genomes and failed to identify other complementary enzymes involved
342 in the degradation of L-fucose and L-rhamnose. However, other enzymes involved in
343 carbohydrate metabolism including glycoside hydrolases, carbohydrate binding module,
344 polysaccharide lyase, carbohydrate esterases and glycoside transferase were detected (**Table**
345 **S4C**) indicating that “*Ca. T. lasonolidus*” is capable of polysaccharide degradation, something
346 that is observed in a number of marine Verrucomicrobia (78–80).

347 A characteristic of obligate host-symbiont relationships is the loss of symbiont genes which are
348 required for independent survival. The early stages of genome reduction are characterized by
349 reduced coding density, and a high number of pseudogenes (81–83). We compared “*Ca. T.*
350 *lasonolidus*” with its closest free-living relative - *Pedosphaera parvula* Ellin514
351 (GCA_000172555.1). The draft genome of *P. parvula* Ellin514 is 7.41Mbp long, about 2.2 Mbp
352 longer than “*Ca. T. lasonolidus*”. Furthermore, in *P. parvula* Ellin514 only 0.5% of total ORFs
353 were found to be pseudogenes (57, 84, 85) as opposed to about 16% in “*Ca. T. lasonolidus*” (**Fig.**
354 **9A-B**). Another indication of ongoing genome reduction comes from the fact that a much smaller
355 percentage of genes with annotated function were identified in “*Ca. T. lasonolidus*” as compared

356 to *P. paruva* Ellin514 (**Fig. 9C**), perhaps indicating sequence degradation and divergence from
357 functionally-annotated genes. Moreover, when compared with *P. paruva* Ellin514, “*Ca. T.*
358 *lasonolidus*” lacks genes involved in DNA repair, DNA replication, chemotaxis and nucleotide
359 metabolism (**Fig. 9D**), a trend which is commonly observed in symbionts undergoing genome
360 reduction (81). However, “*Ca. T. lasonolidus*” contains most of the primary metabolic pathways
361 (**Fig. 9E**) when compared to *P. paruva* Ellin514, and has a fairly large genome to be classified as
362 reduced. Based on the above evidence we suggest that “*Ca. T. lasonolidus*” is in early stages of
363 genome reduction. This hypothesis is also supported by its low coding density of ~72% (without
364 pseudogenes), relative to the average coding density of 85-90% for free-living bacteria (81)
365 which suggests a recent transitional event, such as host restriction (81).

366 Due to its potency and unique mechanism of action, LSA is considered a potential anti-cancer
367 drug lead; however, its limited supply has hampered its transition to clinical trials. The evidence
368 provided here suggests that LSA is synthesized by a yet uncultured Verrucomicrobial symbiont,
369 which harbors three copies of the putative *las* BGC. The detailed analysis of the biosynthetic
370 scheme, genome characteristics of the putative producer as well as the capture of the *las* BGC on
371 a plasmid will aid future cultivation and heterologous expression efforts.

372 **Acknowledgments**

373 The authors acknowledge Amy Wright and Shirley Pomponi for providing sponge specimens,
374 and Amy Wright, Shirley Pomponi and Peter McCarthy for valuable discussions during the
375 project. The authors also thank Samantha C. Waterworth for fruitful discussions, John Barkei for
376 discussions on heterologous expression strategies, and Chase Clark for providing DH sequences
377 for sequence comparisons.

378 **Funding**

379 Support was provided by NCI (R21 CA209189) and a Start-up Fund from Harbor Branch
380 Oceanographic Institute Foundation. The sample used in the study was collected with funds from
381 a grant from the State of Florida Board of Education awarded to Florida Atlantic University for
382 the Center of Excellence in Biomedical and Marine Biotechnology. This material is based upon
383 work supported by the National Science Foundation under Grant No. DBI 1845890.

384 **Data availability**

385 The data associated with this study is deposited under BioProject RJNA833117. The WGS reads
386 have been deposited in the sequence read archive (SRA) with accessions SRR18966768
387 (Forcepia_v1) and SRR18966767 (Forcepia_v2).

388 **Methods**

389 For full details see **Text S1**.

390 **Sponge collection**

391 *Forcepia* sp. (class, *Demospongiae*; order, *Poecilosclerida*; family, *Coelosphaeridae*) was
392 collected in August of 2005 using the HBOI Johnson Sea Link submersible. Samples were
393 collected at a depth of 70m from the Gulf of Mexico (26.256573N, 83.702772W) on the Pulley
394 Ridge (<https://shinyapps.fau.edu/app/bmr>). The sponge samples were immediately frozen at
395 -80°C . The sample ID was 12-VIII-05-1-006 200508121006 2005-08-12 JSL I-4837 (HBOI)
396 *Forcepia* sp. 131921.

397 DNA purification and sequencing

398 The sponge hologenome was extracted using a modified cetyl trimethylammonium bromide
399 (CTAB) DNA extraction method (87) and then size-fractionated by low melting point gel
400 electrophoresis. DNA fragments greater than 40 kb were recovered from the gel and used for
401 fosmid library preparation (**Text S1**) as well as metagenomic sequencing. Two rounds of
402 sequencing were performed for different DNA extracts from the *Forcepia* sp. sponge. For the
403 first round (referred to as Forcepia_v1) Illumina TruSeq DNA libraries were prepared and
404 sequenced by RTL Genomics using an Illumina MiSeq sequencer giving us 108 million paired-
405 end reads with length of 151bp. For the second round of sequencing (referred to as Forcepia_v2)
406 Illumina Nextera libraries were prepared and sequenced using a NovaSeq 6000 sequencer giving
407 us 303 million paired-end reads with length of 150 bp. Fosmids were sequenced by RTL
408 Genomics and Genewiz.

409 Identification and annotation of *las* BGC

410 Identification of the *las* BGC was done using tBLASTN (26), where KS domains from different
411 *trans*-AT PKS pathways were used as a query against the metagenomic assembly (assembled
412 using MetaSpades (88), see **Text S1**). Genes for each bin were called and annotated using
413 Prokka v1 (89, 90). MetaSpades contig headers were replaced by their respective Prokka headers
414 to maintain consistency with the annotation file submitted to NCBI. Genes on contigs making up
415 the *las* BGC were not called correctly by Prokka (89, 90) and were thus annotated manually in
416 Artemis (91) with the help of AntiSMASH (27), CDD (92) and SMART (93, 94).

417 Functional analysis of the “*Ca. T. lasonolidus*” genome

418 Genes called using Prokka v1 were used for all functional analysis (89, 90). PV-BMC clusters
419 were identified in “*Ca. T. lasonolidus*” using Interproscan v5.52-86.0 (95) and CDD (92). Initial
420 identification of ELPs was done using Diamond BLASTP against the diamond-formatted nr
421 database (using -k 1 --max-hsps 1 options) (96) and Interproscan v5.52-86.0 (95). This was
422 followed by verification of non-pseudogenes using CDD (92). Enzymes involved in
423 carbohydrate metabolism were detected using dbCAN2 (97) where genes annotated by ≥ 2 tools
424 (out of HMMER, Diamond and Hotpep) were kept. COG categories were identified using the
425 eggNOG mapper online server (98, 99).

426 The genome of *P. paruva* Ellin514 was downloaded from Genbank (GCA_000172555.1) and
427 genes were called and annotated using Prokka v1 (89, 90). Primary metabolic pathways were
428 identified for non-pseudogenes with kofamscan using the --mapper flag (100) and annotated
429 against the KEGG database (101–103). The matrix with presence/absence of different enzymes
430 was constructed in RStudio (104). Completeness of metabolic pathways was identified using
431 KEGG-Decoder (86).

432 References

- 433 1. Horton PA, Koehn FE, Longley RE, McConnell OJ. 1994. Lasonolide A, a new cytotoxic
434 macrolide from the marine sponge *Forcepia* sp. *J Am Chem Soc* 116:6015–6016.
- 435 2. Wright AE, Chen Y, Winder PL, Pitts TP, Pomponi SA, Longley RE. 2004. Lasonolides C-
436 G, five new lasonolide compounds from the sponge *Forcepia* sp. *J Nat Prod* 67:1351–1355.
- 437 3. Isbrucker RA, Guzmán EA, Pitts TP, Wright AE. 2009. Early effects of lasonolide A on

- 438 pancreatic cancer cells. *J Pharmacol Exp Ther* 331:733–739.
- 439 4. Jossé R, Zhang Y-W, Giroux V, Ghosh AK, Luo J, Pommier Y. 2015. Activation of RAF1
440 (c-RAF) by the marine alkaloid lasonolide A induces rapid premature chromosome
441 condensation. *Mar Drugs* 13:3625–3639.
- 442 5. Zhang Y-W, Ghosh AK, Pommier Y. 2012. Lasonolide A, a potent and reversible inducer
443 of chromosome condensation. *Cell Cycle* 11:4424–4435.
- 444 6. Yang L, Lin Z, Shao S, Zhao Q, Hong R. 2018. An enantioconvergent and concise synthesis
445 of lasonolide A. *Angew Chem Int Ed Engl* 57:16200–16204.
- 446 7. Yang L, Lin Z, Shao S, Zhao Q, Hong R. 2019. Corrigendum: An enantioconvergent and
447 concise synthesis of lasonolide A. *Angew Chem Int Ed Engl* 58:4431.
- 448 8. Trost BM, Stivala CE, Fandrick DR, Hull KL, Huang A, Poock C, Kalkofen R. 2016. Total
449 synthesis of (-)-lasonolide A. *J Am Chem Soc* 138:11690–11701.
- 450 9. Piel J. 2009. Metabolites from symbiotic bacteria. *Nat Prod Rep* 26:338–362.
- 451 10. Lopanik NB. 2014. Chemical defensive symbioses in the marine environment. *Funct Ecol*
452 28:328–340.
- 453 11. Flórez LV, Biedermann PHW, Engl T, Kaltenpoth M. 2015. Defensive symbioses of
454 animals with prokaryotic and eukaryotic microorganisms. *Nat Prod Rep* 32:904–936.
- 455 12. Oliver KM, Smith AH, Russell JA. 2014. Defensive symbiosis in the real world - advancing
456 ecological studies of heritable, protective bacteria in aphids and beyond. *Funct Ecol*
457 28:341–355.

- 458 13. Bodor A, Bounedjoum N, Vincze GE, Erdeiné Kis Á, Laczi K, Bende G, Szilágyi Á,
459 Kovács T, Perei K, Rákhely G. 2020. Challenges of unculturable bacteria: Environmental
460 perspectives. *Rev Environ Sci Technol* 19:1–22.
- 461 14. Hofer U. 2018. The majority is uncultured. *Nat Rev Microbiol* 16:716–717.
- 462 15. Vartoukian SR, Palmer RM, Wade WG. 2010. Strategies for culture of “unculturable”
463 bacteria. *FEMS Microbiol Lett* 309:1–7.
- 464 16. Stevens DC, Hari TPA, Boddy CN. 2013. The role of transcription in heterologous
465 expression of polyketides in bacterial hosts. *Nat Prod Rep* 30:1391–1411.
- 466 17. Trindade M, van Zyl LJ, Navarro-Fernández J, Abd Elrazak A. 2015. Targeted
467 metagenomics as a tool to tap into marine natural product diversity for the discovery and
468 production of drug candidates. *Front Microbiol* 6:890.
- 469 18. Nivina A, Yuet KP, Hsu J, Khosla C. 2019. Evolution and diversity of assembly-line
470 polyketide synthases. *Chem Rev* 119:12524–12547.
- 471 19. Cox RJ. 2007. Polyketides, proteins and genes in fungi: Programmed nano-machines begin
472 to reveal their secrets. *Org Biomol Chem* 5:2010–2026.
- 473 20. Jenke-Kodama H, Sandmann A, Müller R, Dittmann E. 2005. Evolutionary implications of
474 bacterial polyketide synthases. *Mol Biol Evol* 22:2027–2039.
- 475 21. Calderone CT, Kowtoniuk WE, Kelleher NL, Walsh CT, Dorrestein PC. 2006.
476 Convergence of isoprene and polyketide biosynthetic machinery: Isoprenyl-S-carrier
477 proteins in the *pksX* pathway of *Bacillus subtilis*. *Proc Natl Acad Sci U S A* 103:8977–

- 478 8982.
- 479 22. Calderone CT. 2008. Isoprenoid-like alkylations in polyketide biosynthesis. *Nat Prod Rep*
480 25:845–853.
- 481 23. Gu L, Wang B, Kulkarni A, Geders TW, Grindberg RV, Gerwick L, Håkansson K, Wipf P,
482 Smith JL, Gerwick WH, Sherman DH. 2009. Metamorphic enzyme assembly in polyketide
483 diversification. *Nature* 459:731–735.
- 484 24. Helfrich EJN, Piel J. 2016. Biosynthesis of polyketides by *trans*-AT polyketide synthases.
485 *Nat Prod Rep* 33:231–316.
- 486 25. Bowers RM, Kyrpides NC, Stepanauskas R, Harmon-Smith M, Doud D, Reddy TBK,
487 Schulz F, Jarett J, Rivers AR, Eloie-Fadrosch EA, Tringe SG, Ivanova NN, Copeland A,
488 Clum A, Becraft ED, Malmstrom RR, Birren B, Podar M, Bork P, Weinstock GM, Garrity
489 GM, Dodsworth JA, Yooseph S, Sutton G, Glöckner FO, Gilbert JA, Nelson WC, Hallam
490 SJ, Jungbluth SP, Ettema TJG, Tighe S, Konstantinidis KT, Liu W-T, Baker BJ, Rattei T,
491 Eisen JA, Hedlund B, McMahon KD, Fierer N, Knight R, Finn R, Cochrane G, Karsch-
492 Mizrachi I, Tyson GW, Rinke C, Lapidus A, Meyer F, Yilmaz P, Parks DH, Murat Eren A,
493 Schriml L, Banfield JF, Hugenholtz P, Woyke T. 2017. Minimum information about a
494 single amplified genome (MISAG) and a metagenome-assembled genome (MIMAG) of
495 bacteria and archaea. *Nat Biotechnol* 35:725–731.
- 496 26. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009.
497 BLAST+: Architecture and applications. *BMC Bioinform* 10:1–9.
- 498 27. Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, Lee SY, Medema MH, Weber T. 2019.

- 499 antiSMASH 5.0: Updates to the secondary metabolite genome mining pipeline. *Nucleic*
500 *Acids Res* 47:W81–W87.
- 501 28. Gilchrist CLM, Chooi Y-H. 2021. Clinker & clustermap.js: Automatic generation of gene
502 cluster comparison figures. *Bioinformatics* 37:2473–2475.
- 503 29. Wick RR, Schultz MB, Zobel J, Holt KE. 2015. Bandage: Interactive visualization of *de*
504 *novo* genome assemblies. *Bioinformatics* 31:3350–3352.
- 505 30. Chaumeil P-A, Mussig AJ, Hugenholtz P, Parks DH. 2020. GTDB-Tk: A toolkit to classify
506 genomes with the Genome Taxonomy Database. *Bioinformatics* 36:1925–1927.
- 507 31. Yarza P, Yilmaz P, Pruesse E, Glöckner FO, Ludwig W, Schleifer K-H, Whitman WB,
508 Euzéby J, Amann R, Rosselló-Móra R. 2014. Uniting the classification of cultured and
509 uncultured bacteria and archaea using 16S rRNA gene sequences. *Nat Rev Microbiol*
510 12:635–645.
- 511 32. Navarro-Muñoz JC, Selem-Mojica N, Mullaney MW, Kautsar SA, Tryon JH, Parkinson
512 EI, De Los Santos ELC, Yeong M, Cruz-Morales P, Abubucker S, Roeters A, Lokhorst W,
513 Fernandez-Guerra A, Cappelini LTD, Goering AW, Thomson RJ, Metcalf WW, Kelleher
514 NL, Barona-Gomez F, Medema MH. 2020. A computational framework to explore large-
515 scale biosynthetic diversity. *Nat Chem Biol* 16:60–68.
- 516 33. Nguyen T, Ishida K, Jenke-Kodama H, Dittmann E, Gurgui C, Hochmuth T, Taudien S,
517 Platzer M, Hertweck C, Piel J. 2008. Exploiting the mosaic structure of *trans*-
518 acyltransferase polyketide synthases for natural product discovery and pathway dissection.
519 *Nat Biotechnol* 26:225–233.

- 520 34. Jensen K, Niederkrüger H, Zimmermann K, Vagstad AL, Moldenhauer J, Brendel N, Frank
521 S, Pöplau P, Kohlhaas C, Townsend CA, Oldiges M, Hertweck C, Piel J. 2012. Polyketide
522 proofreading by an acyltransferase-like enzyme. *Chem Biol* 19:329–339.
- 523 35. Jenner M, Afonso JP, Kohlhaas C, Karbaum P, Frank S, Piel J, Oldham NJ. 2016. Acyl
524 hydrolases from *trans*-AT polyketide synthases target acetyl units on acyl carrier proteins.
525 *Chem Commun* 52:5262–5265.
- 526 36. Piel J. 2010. Biosynthesis of polyketides by *trans*-AT polyketide synthases. *Nat Prod Rep*
527 27:996–1047.
- 528 37. Haines AS, Dong X, Song Z, Farmer R, Williams C, Hothersall J, Płoskoń E, Wattana-
529 Amorn P, Stephens ER, Yamada E, Gurney R, Takebayashi Y, Masschelein J, Cox RJ,
530 Lavigne R, Willis CL, Simpson TJ, Crosby J, Winn PJ, Thomas CM, Crump MP. 2013. A
531 conserved motif flags acyl carrier proteins for β -branching in polyketide synthesis. *Nat*
532 *Chem Biol* 9:685–692.
- 533 38. Walker PD, Weir ANM, Willis CL, Crump MP. 2021. Polyketide β -branching: Diversity,
534 mechanism and selectivity. *Nat Prod Rep* 38:723–756.
- 535 39. Slocum ST, Lowell AN, Tripathi A, Shende VV, Smith JL, Sherman DH. 2018.
536 Chemoenzymatic dissection of polyketide β -branching in the bryostatin pathway, p. 207–
537 236. *In* Moore, BS (ed.), *Marine Enzymes and Specialized Metabolism - Part A*. Academic
538 Press.
- 539 40. Gu L, Jia J, Liu H, Håkansson K, Gerwick WH, Sherman DH. 2006. Metabolic coupling of
540 dehydration and decarboxylation in the curacin A pathway: Functional identification of a

- 541 mechanistically diverse enzyme pair. *J Am Chem Soc* 128:9014–9015.
- 542 41. Matilla MA, Stöckmann H, Leeper FJ, Salmond GPC. 2012. Bacterial biosynthetic gene
543 clusters encoding the anti-cancer haterumalide class of molecules: Biogenesis of the broad
544 spectrum antifungal and anti-oomycete compound, oocydin A. *J Biol Chem* 287:39125–
545 39138.
- 546 42. Kačar D, Cañedo LM, Rodríguez P, González EG, Galán B, Schleissner C, Leopold-Messer
547 S, Piel J, Cuevas C, de la Calle F, García JL. 2021. Identification of *trans*-AT polyketide
548 clusters in two marine bacteria reveals cryptic similarities between distinct symbiosis
549 factors. *Environ Microbiol* 23:2509–2521.
- 550 43. Meoded RA, Ueoka R, Helfrich EJN, Jensen K, Magnus N, Piechulla B, Piel J. 2018. A
551 polyketide synthase component for oxygen insertion into polyketide backbones. *Angew*
552 *Chem Int Ed Engl* 57:11644–11648.
- 553 44. Hemmerling F, Meoded RA, Fraley AE, Minas HA, Dieterich CL, Rust M, Ueoka R,
554 Jensen K, Helfrich EJN, Bergande C, Biedermann M, Magnus N, Piechulla B, Piel J. 2022.
555 Modular halogenation, α -hydroxylation, and acylation by a remarkably versatile polyketide
556 synthase. *Angew Chem Int Ed Engl* 61:e202116614.
- 557 45. Greule A, Stok JE, De Voss JJ, Cryle MJ. 2018. Unrivalled diversity: The many roles and
558 reactions of bacterial cytochromes P450 in secondary metabolism. *Nat Prod Rep* 35:757–
559 791.
- 560 46. Bumpus SB, Magarvey NA, Kelleher NL, Walsh CT, Calderone CT. 2008. Polyunsaturated
561 fatty-acid-like *trans*-enoyl reductases utilized in polyketide biosynthesis. *J Am Chem Soc*

- 562 130:11614–11616.
- 563 47. Flórez LV, Scherlach K, Miller IJ, Rodrigues A, Kwan JC, Hertweck C, Kaltenpoth M.
564 2018. An antifungal polyketide associated with horizontally acquired genes supports
565 symbiont-mediated defense in *Lagria villosa* beetles. Nat Commun 9:2478.
- 566 48. Kwan JC, Donia MS, Han AW, Hirose E, Haygood MG, Schmidt EW. 2012. Genome
567 streamlining and chemical defense in a coral reef symbiosis. Proc Natl Acad Sci USA
568 109:20655–20660.
- 569 49. Chen X-H, Vater J, Piel J, Franke P, Scholz R, Schneider K, Koumoutsi A, Hitzeroth G,
570 Grammel N, Strittmatter AW, Gottschalk G, Süssmuth RD, Borriss R. 2006. Structural and
571 functional characterization of three polyketide synthase gene clusters in *Bacillus*
572 *amyloliquefaciens* FZB 42. J Bacteriol 188:4024–4036.
- 573 50. Keatinge-Clay AT. 2007. A tylosin ketoreductase reveals how chirality is determined in
574 polyketides. Chem Biol 14:898–908.
- 575 51. Caffrey P. 2003. Conserved amino acid residues correlating with ketoreductase
576 stereospecificity in modular polyketide synthases. ChemBioChem 4:654–657.
- 577 52. Pöplau P, Frank S, Morinaka BI, Piel J. 2013. An enzymatic domain for the formation of
578 cyclic ethers in complex polyketides. Angew Chem Int Ed Engl 52:13215–13218.
- 579 53. Wagner DT, Zhang Z, Meoded RA, Cepeda AJ, Piel J, Keatinge-Clay AT. 2018. Structural
580 and functional studies of a pyran synthase domain from a *trans*-acyltransferase assembly
581 line. ACS Chem Biol 13:975–983.

- 582 54. Gay DC, Spear PJ, Keatinge-Clay AT. 2014. A double-hotdog with a new trick: Structure
583 and mechanism of the *trans*-acyltransferase polyketide synthase enoyl-isomerase. ACS
584 Chem Biol 9:2374–2381.
- 585 55. Dubey R, Stivala CE, Nguyen HQ, Goo Y-H, Paul A, Carette JE, Trost BM, Rohatgi R.
586 2020. Lipid droplets can promote drug accumulation and activation. Nat Chem Biol
587 16:206–213.
- 588 56. Albertsen M, Hugenholtz P, Skarshewski A, Nielsen KL, Tyson GW, Nielsen PH. 2013.
589 Genome sequences of rare, uncultured bacteria obtained by differential coverage binning of
590 multiple metagenomes. Nat Biotechnol 31:533–538.
- 591 57. Lopera J, Miller IJ, McPhail KL, Kwan JC. 2017. Increased biosynthetic gene dosage in a
592 genome-reduced defensive bacterial symbiont. mSystems 2:e00096–17.
- 593 58. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A,
594 Jordan T, Shakir K, Roazen D, Thibault J, Banks E, Garimella KV, Altshuler D, Gabriel S,
595 DePristo MA. 2013. From FastQ data to high-confidence variant calls: The genome analysis
596 toolkit best practices pipeline. Curr Protoc Bioinform 43:11.10.1–11.10.30.
- 597 59. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del
598 Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM, Sivachenko AY,
599 Cibulskis K, Gabriel SB, Altshuler D, Daly MJ. 2011. A framework for variation discovery
600 and genotyping using next-generation DNA sequencing data. Nat Genet 43:491–498.
- 601 60. Miller IJ, Rees ER, Ross J, Miller I, Baxa J, Lopera J, Kerby RL, Rey FE, Kwan JC. 2019.
602 Autometa: Automated extraction of microbial genomes from individual shotgun

- 603 metagenomes. *Nucleic Acids Res* 47:e57.
- 604 61. Dick GJ, Andersson AF, Baker BJ, Simmons SL, Thomas BC, Yelton AP, Banfield JF.
605 2009. Community-wide analysis of microbial genome sequence signatures. *Genome Biol*
606 10:R85.
- 607 62. Laczny CC, Pinel N, Vlassis N, Wilmes P. 2014. Alignment-free visualization of
608 metagenomic data by nonlinear dimension reduction. *Sci Rep* 4:4516.
- 609 63. Sharp PM, Li W-H. 1987. The codon adaptation index—a measure of directional
610 synonymous codon usage bias, and its potential applications. *Nucleic Acids Res* 15:1281–
611 1295.
- 612 64. Avalon NE, Murray AE, Daligault HE, Lo C-C, Davenport KW, Dichosa AEK, Chain PSG,
613 Baker BJ. 2021. Bioinformatic and mechanistic analysis of the palmerolide PKS-NRPS
614 biosynthetic pathway from the microbiome of an Antarctic ascidian. *Front Chem* 9:802574.
- 615 65. Murray AE, Lo C-C, Daligault HE, Avalon NE, Read RW, Davenport KW, Higham ML,
616 Kunde Y, Dichosa AEK, Baker BJ, Chain PSG. 2021. Discovery of an Antarctic ascidian-
617 associated uncultivated Verrucomicrobia with antimelanoma palmerolide biosynthetic
618 potential. *mSphere* 6:e00759–21.
- 619 66. Michael R, N. HEJ, F. FM, Pakjira N, M. FC, Christian R, Tomas K, J. PM, L. WV, Jörn K,
620 Shinichi S, Jörn P. 2020. A multiproducer microbiome generates chemical diversity in the
621 marine sponge *Mycale hentscheli*. *Proc Natl Acad Sci U S A* 117:9508–9518.
- 622 67. Storey MA, Andreassend SK, Bracegirdle J, Brown A, Keyzers RA, Ackerley DF,

- 623 Northcote PT, Owen JG. 2020. Metagenomic exploration of the marine sponge *Mycale*
624 *hentscheli* uncovers multiple polyketide-producing bacterial symbionts. *mBio* 11:e02997–
625 19.
- 626 68. Spring S, Bunk B, Spröer C, Schumann P, Rohde M, Tindall BJ, Klenk H-P. 2016.
627 Characterization of the first cultured representative of Verrucomicrobia subdivision 5
628 indicates the proposal of a novel phylum. *ISME J* 10:2801–2816.
- 629 69. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. CheckM:
630 Assessing the quality of microbial genomes recovered from isolates, single cells, and
631 metagenomes. *Genome Res* 25:1043–1055.
- 632 70. Burgsdorf I, Handley KM, Bar-Shalom R, Erwin PM, Steindler L. 2019. Life at home and
633 on the roam: Genomic adaptations reflect the dual lifestyle of an intracellular, facultative
634 symbiont. *mSystems* 4:e00057–19.
- 635 71. Sizikov S, Burgsdorf I, Handley KM, Lahyani M, Haber M, Steindler L. 2020.
636 Characterization of sponge-associated Verrucomicrobia: Microcompartment-based sugar
637 utilization and enhanced toxin-antitoxin modules as features of host-associated Opitutales.
638 *Environ Microbiol* 22:4669–4688.
- 639 72. Frank AC. 2019. Molecular host mimicry and manipulation in bacterial symbionts. *FEMS*
640 *Microbiol Lett* 366:fnz038.
- 641 73. Díez-Vives C, Moitinho-Silva L, Nielsen S, Reynolds D, Thomas T. 2017. Expression of
642 eukaryotic-like protein in the microbiome of sponges. *Mol Ecol* 26:1432–1451.

- 643 74. Nguyen MTHD, Liu M, Thomas T. 2014. Ankyrin-repeat proteins from sponge symbionts
644 modulate amoebal phagocytosis. *Mol Ecol* 23:1635–1645.
- 645 75. Kerfeld CA, Aussignargues C, Zarzycki J, Cai F, Sutter M. 2018. Bacterial
646 microcompartments. *Nat Rev Microbiol* 16:277–290.
- 647 76. Erbilgin O, McDonald KL, Kerfeld CA. 2014. Characterization of a planctomycetal
648 organelle: A novel bacterial microcompartment for the aerobic degradation of plant
649 saccharides. *Appl Environ Microbiol* 80:2193–2205.
- 650 77. Sichert A, Corzett CH, Schechter MS, Unfried F, Markert S, Becher D, Fernandez-Guerra
651 A, Liebeke M, Schweder T, Polz MF, Hehemann J-H. 2020. Verrucomicrobia use hundreds
652 of enzymes to digest the algal polysaccharide fucoidan. *Nat Microbiol* 5:1026–1039.
- 653 78. Cardman Z, Arnosti C, Durbin A, Ziervogel K, Cox C, Steen AD, Teske A. 2014.
654 Verrucomicrobia are candidates for polysaccharide-degrading bacterioplankton in an arctic
655 fjord of Svalbard. *Appl Environ Microbiol* 80:3749–3756.
- 656 79. Martinez-Garcia M, Brazel DM, Swan BK, Arnosti C, Chain PSG, Reitenga KG, Xie G,
657 Poulton NJ, Lluesma Gomez M, Masland DED, Thompson B, Bellows WK, Ziervogel K,
658 Lo C-C, Ahmed S, Gleasner CD, Detter CJ, Stepanauskas R. 2012. Capturing single cell
659 genomes of active polysaccharide degraders: An unexpected contribution of
660 Verrucomicrobia. *PLoS One* 7:e35314.
- 661 80. Herlemann DPR, Lundin D, Labrenz M, Jürgens K, Zheng Z, Aspeborg H, Andersson AF.
662 2013. Metagenomic *de novo* assembly of an aquatic representative of the verrucomicrobial
663 class *Spartobacteria*. *mBio* 4:e00569–12.

- 664 81. McCutcheon JP, Moran NA. 2011. Extreme genome reduction in symbiotic bacteria. Nat
665 Rev Microbiol 10:13–26.
- 666 82. Lo W-S, Huang Y-Y, Kuo C-H. 2016. Winding paths to simplicity: Genome evolution in
667 facultative insect symbionts. FEMS Microbiol Rev 40:855–874.
- 668 83. Dietel A-K, Merker H, Kaltenpoth M, Kost C. 2019. Selective advantages favour high
669 genomic AT-contents in intracellular elements. PLoS Genet 15:e1007778.
- 670 84. Lerat E, Ochman H. 2005. Recognizing the pseudogenes in bacterial genomes. Nucleic
671 Acids Res 33:3125–3132.
- 672 85. Waterworth SC, Flórez LV, Rees ER, Hertweck C, Kaltenpoth M, Kwan JC. 2020.
673 Horizontal gene transfer to a defensive symbiont with a reduced genome in a multipartite
674 beetle microbiome. mBio 11:e02430–19.
- 675 86. Graham ED, Heidelberg JF, Tully BJ. 2018. Potential for primary productivity in a
676 globally-distributed bacterial phototroph. ISME J 12:1861–1866.
- 677 87. Piel J, Hui D, Wen G, Butzke D, Platzer M, Fusetani N, Matsunaga S. 2004. Antitumor
678 polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge
679 *Theonella swinhoei*. Proc Natl Acad Sci U S A 101:16222–16227.
- 680 88. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. 2017. metaSPAdes: A new versatile
681 metagenomic assembler. Genome Res 27:824–834.
- 682 89. Seemann T. 2014. Prokka: Rapid prokaryotic genome annotation. Bioinformatics 30:2068–
683 2069.

- 684 90. Hyatt D, Chen G-L, Locascio PF, Land ML, Larimer FW, Hauser LJ. 2010. Prodigal:
685 Prokaryotic gene recognition and translation initiation site identification. *BMC Bioinform*
686 11:119.
- 687 91. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA. 2012. Artemis: An integrated
688 platform for visualization and analysis of high-throughput sequence-based experimental
689 data. *Bioinformatics* 28:464–469.
- 690 92. Lu S, Wang J, Chitsaz F, Derbyshire MK, Geer RC, Gonzales NR, Gwadz M, Hurwitz DI,
691 Marchler GH, Song JS, Thanki N, Yamashita RA, Yang M, Zhang D, Zheng C, Lanczycki
692 CJ, Marchler-Bauer A. 2020. CDD/SPARCLE: The conserved domain database in 2020.
693 *Nucleic Acids Res* 48:D265–D268.
- 694 93. Letunic I, Khedkar S, Bork P. 2021. SMART: Recent updates, new developments and status
695 in 2020. *Nucleic Acids Res* 49:D458–D460.
- 696 94. Letunic I, Bork P. 2018. 20 years of the SMART protein domain annotation resource.
697 *Nucleic Acids Res* 46:D493–D496.
- 698 95. Jones P, Binns D, Chang H-Y, Fraser M, Li W, McAnulla C, McWilliam H, Maslen J,
699 Mitchell A, Nuka G, Pesseat S, Quinn AF, Sangrador-Vegas A, Scheremetjew M, Yong S-
700 Y, Lopez R, Hunter S. 2014. InterProScan 5: Genome-scale protein function classification.
701 *Bioinformatics* 30:1236–1240.
- 702 96. Buchfink B, Reuter K, Drost H-G. 2021. Sensitive protein alignments at tree-of-life scale
703 using DIAMOND. *Nat Methods* 18:366–368.

- 704 97. Zhang H, Yohe T, Huang L, Entwistle S, Wu P, Yang Z, Busk PK, Xu Y, Yin Y. 2018.
705 dbCAN2: A meta server for automated carbohydrate-active enzyme annotation. *Nucleic*
706 *Acids Res* 46:W95–W101.
- 707 98. Cantalapiedra CP, Hernández-Plaza A, Letunic I, Bork P, Huerta-Cepas J. 2021. eggNOG-
708 mapper v2: Functional annotation, orthology assignments, and domain prediction at the
709 metagenomic scale. *Mol Biol Evol* 38:5825–5829.
- 710 99. Huerta-Cepas J, Szklarczyk D, Heller D, Hernández-Plaza A, Forslund SK, Cook H, Mende
711 DR, Letunic I, Rattei T, Jensen LJ, von Mering C, Bork P. 2019. eggNOG 5.0: A
712 hierarchical, functionally and phylogenetically annotated orthology resource based on 5090
713 organisms and 2502 viruses. *Nucleic Acids Res* 47:D309–D314.
- 714 100. Aramaki T, Blanc-Mathieu R, Endo H, Ohkubo K, Kanehisa M, Goto S, Ogata H. 2020.
715 KofamKOALA: KEGG ortholog assignment based on profile HMM and adaptive score
716 threshold. *Bioinformatics* 37:2251–2252.
- 717 101. Kanehisa M, Sato Y. 2020. KEGG Mapper for inferring cellular functions from protein
718 sequences. *Protein Sci* 29:28–35.
- 719 102. Kanehisa M, Sato Y, Kawashima M. 2021. KEGG mapping tools for uncovering hidden
720 features in biological data. *Protein Sci* 31:47–52.
- 721 103. Kanehisa M, Goto S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic*
722 *Acids Res* 28:27–30.
- 723 104. Team R. 2020. RStudio: Integrated Development for R. RStudio, PBC, Boston, MA.

725 **Figure Legends**

726 **Fig. 1.** (A) Sponge *Forcepia* sp. as seen in the field. (B) The *Forcepia* sp. specimen used for
727 DNA extraction (sample ID: 12-VIII-05-1-6). Photo credit: HBOI Marine Biomedical and
728 Biotechnology Program. (C) The chemical structures of lasonolide A (LSA) and its analogs.

729 **Fig. 2.** (A) Collection site of *Forcepia* sp. sponge (dark red diamond, 26.256573N,
730 83.702772W). (B) Features in lasonolide A (LSA) characteristic of biosynthesis by a *trans*-AT
731 PKS pathway. (C) Relative abundance of different phyla in the sequenced *Forcepia_v1*
732 metagenome. Each block shows the relative abundance of each metagenome-assembled genome
733 (MAG), with colors representing the phylum they belong to. The *las* biosynthetic gene cluster
734 (BGC)-carrying bin is marked with a star. (D) BGC distribution in *Forcepia_v1* sp. metagenome.
735 AntiSMASH (27) annotations of bacterial contigs greater than 500 bp are shown. Each bar
736 indicates a MAG. Bars have been grouped by phylum. The star represents the MAG possessing
737 *las* BGC. BGC annotations have been simplified into polyketide synthase (PKS), Type 1 PKS,
738 Type 3 PKS, *trans*-AT PKS, nonribosomal peptide synthetase (NRPS), ribosomally synthesized,
739 post-translationally modified peptide (RiPP), hgIE-KS, hgIE-KS-T1PKS, terpenes, RiPP-terpene
740 and others. (E) Comparison of *las* BGC_v1 and *las* BGC_v2 using clinker (28). V1 refers to *las*
741 BGC_v1 while V2 refers to *las* BGC_v2. Numbers in the boxes indicate amino acid identity as a
742 fraction of 1.

743 **Fig. 3. Proposed LSA biosynthetic scheme.** Colored lines above the *las* BGC represent an
744 alignment of individual fosmids to the pathway, the fosmids were subsequently assembled
745 together in a plasmid. A cross indicates a domain predicted to be catalytically inactive. Open
746 reading frames colored in gray represent genes with unknown or no role in LSA synthesis.

747 Numbers below domains indicate the module number and ‘A’ and ‘B’ denote the predicted
748 stereoconfiguration of the KR product, as previously described (50, 51). Predicted substrate
749 specificity of KS domains, obtained through phylogeny (**Fig. S3**) (33), are shown above each
750 respective KS domain. Carbon 31 is highlighted in blue to represent the site where P450 LasP is
751 predicted to act. Abbreviations: ACP, acyl carrier protein, also denoted by a filled black circle;
752 AH, acylhydrolase; AT, acyltransferase; C, condensation; DH, dehydratase; ECH, enoyl-CoA
753 reductase; ER, enoylreductase; HMGS, 3-hydroxy-3-methylglutaryl-CoA synthase; KR,
754 ketoreductase; KS, ketosynthase; MOX, monooxygenase; PS, pyransynthase; P450, cytochrome
755 P450; THP, Tetrahydropyran.

756 **Fig. 4.** Proposed biosynthesis of different analogs from lasonolide A. We could not identify an
757 enzyme which would explain the migration of the methyl from C-38 in LSA to C-36 in
758 lasonolide B.

759 **Fig. 5.** Model for three repeats of the *las* BGC. The 5' end of *las* BGC is highlighted to
760 demonstrate the location where one of the *las* BGC repeats lacks *lasC*. Contig(s) making up the
761 98 kbp segment of *las* BGC (one in *las* BGC_v1 and six in *las* BGC_v2) have been collectively
762 referred to as contig 1. Contigs except for the *las* BGC are not shown to scale.

763 **Fig. 6.** Variants identified between the three repeats of *las* BGC_v1.

764 **Fig. 7. (A)** 2D visualization of Automata binning of Forcepia_v1. The “*Ca. T. lasonolidus*”
765 genome is circled in black and the *las* BGC contigs are marked with an arrow. Axes represent
766 dimension-reduced Barnes-Hut Stochastic Neighbor Embedding (BH-tSNE) values (BH-tSNE x
767 and BH-tSNE y). **(B)** 3D visualization of contigs present in “*Ca. T. lasonolidus*”. The *las* BGC is
768 colored red. Axes represent BH-tSNE values (BH-tSNE x and BH-tSNE y) along with k-mer

769 coverage. (C) GC percentage of different sets of genes in Forcepia_v1 “*Ca. T. lasonolidus*”. The
770 *las* BGC genes are colored in red.

771 **Fig. 8.** Comparison of PV BMC gene cluster in Forcepia_v1 “*Ca. T. lasonolidus*” with the PV
772 BMC cluster from other Verrucomicrobia. “*Ca. T. lasonolidus*” has DNA-methyltransferase and
773 PVUII endonuclease genes (in gray, labeled 1 and 2) between the first and the second BMC-H
774 genes. This kind of arrangement was not observed in other PV BMC clusters.

775 **Fig. 9. (A and B)** Comparison of the gene length in (A) Forcepia_v1 “*Ca. T. lasonolidus*” and
776 (B) Forcepia_v2 “*Ca. T. lasonolidus*”, respectively with their closest homologs in the nr
777 database. Genes with length less than 80% of the closest homolog (below the lower black line)
778 are classified as putative pseudogenes (57, 84, 85). The graphs have been truncated for clarity, as
779 some genes are many kbp long. (C) Comparison of functional COG categories in Forcepia_v1
780 “*Ca. T. lasonolidus*”, Forcepia_v2 “*Ca. T. lasonolidus*” and *P. paruva* Ellin514 for non-
781 pseudogenes. A gene is considered to have a functional annotation when it belongs to a COG
782 category, except for category S which represents unknown function. (D) Comparison of genes in
783 different metabolic pathways for Forcepia_v1 “*Ca. T. lasonolidus*”, Forcepia_v2 “*Ca. T.*
784 *lasonolidus*” and *P. paruva* Ellin514, including only non-pseudogenes. Colored squares represent
785 presence of a gene while white squares represent absence of gene. *K00940 is involved in both
786 purine and pyrimidine metabolism. Genes absent in all three genomes have been removed. (E)
787 Comparison of completeness of different metabolic pathways in Forcepia_v1 “*Ca. T.*
788 *lasonolidus*”, Forcepia_v2 “*Ca. T. lasonolidus*” and *P. paruva* Ellin514 (including only non-
789 pseudogenes) as determined by KEGG decoder (86). Pathways have been grouped into
790 categories wherever possible. Pathways absent in all three genomes have been removed. V1 and
791 V2 refer to Forcepia_v1 “*Ca. T. lasonolidus*” and Forcepia_v2 “*Ca. T. lasonolidus*” respectively.

792 **Table 1.** Description of the variants identified between the three repeats of *las* BGC_v1. Both
 793 AD and PL values are represented in the manner “reference, variant”. A lower PL value
 794 represents a higher likelihood of the sample being that genotype.

ID	Location (bp)	Change	Length (bp)	Allelic depth	PL
Insertion 1	Between 15,246 and 15,247	+GGAGGATGGGGTGGAGGA TGGGGTGGAGGATGGGGTG GAGGATGGGGTGGAGGATG GGGT	60	7, 15	1129, 0
Insertion 2	Between 24,776 and 24,777	+GGGGTCGGATGGGGGGTTC GGATGG	24	8, 57	3092, 0
Insertion 3	Between 67,976 and 67,977	+GCGGCGGTTGAGGCGGAG GCGGCGGTTGAGGCGGAGG CGGCGGTTGAGGCGGAG	54	23, 164	5987, 0
SNP 1	93,995	G → A	1	363, 457	2973, 0
SNP 2	95,154	A → G	1	175, 621	16101, 0

795 **Table 2.** Genome statistics for “*Ca. T. lasonolidus*”. *Coding density is weighted by length
 796 taking into account the 97.11% coding density of *las* BGC repeats.

Characteristic	Forcepia_v1 “Ca. T. lasonolidus”	Forcepia_v2 “Ca. T. lasonolidus”
Size	4.85 Mbp	4.93 Mbp
Size after adding the three <i>las</i> repeats	5.05 Mbp	5.13 Mbp
checkM completeness	99.24%	99.32%
checkM contamination	1.35%	1.35%
No. of contigs	144	92
Longest contig	204,102 bp	649,894 bp
N50	52,980 bp	96,223
Average GC percentage	53.81%	53.88%
Percentage of pseudogenes	16.31% of total ORFs	16.62% of total ORFs
Transposase genes	6	15
Coding density*	79.45%	79.41%
Coding density without pseudogenes*	72.58%	72.38%
Eukaryotic like proteins		

Ankyrin repeats	3	3
Tetratricopeptide repeat	43 (9 were Sel-1 repeats)	42 (9 were Sel-1 repeats)
Pyrrolo-quinoline quinone	21	21
Leucine-rich repeat	16	16
WD40	4	5

797

798

799 Legend for supplementary material

800 **Fig S1. (A)** Alignment of fosmid to the *las* BGC. Fosmids are depicted as arrows above the *las*
801 BGC. Fosmids captured before WGS are colored orange (3-46, 5-16, 6-17, 4-77 and 1-80),
802 whereas fosmids captured after WGS are colored blue (5-41, 2-18, and 2-13). **(B)** Relative
803 abundance of different phyla in the sequenced *Forcepia_v2* metagenome. Each block shows the
804 relative abundance of each metagenome-assembled genome (MAG), with different colors
805 representing the phylum they belong to. The *las* BGC-carrying bin is highlighted is marked with
806 a star. **(C)** Assembly graph of *las* BGC_v1 visualized in BANDAGE (Wick RR, Schultz MB,
807 Zobel J, Holt KE, Bioinformatics 31:3350–3352, 2015,
808 <https://doi.org/10.1093/bioinformatics/btv383>). **(D)** Mapping of paired-end reads to contigs
809 making up *las* BGC_v1. Contigs in green boxes represent the *las* BGC, red boxes represent the 5'
810 end of *las* BGC and blue boxes represent the 3' end of *las* BGC. **(E)** Assembly of the seven
811 contigs making up *las* BGC_v2. **(F)** Assembly graph of *las* BGC_v2 visualized in BANDAGE
812 (Wick RR, Schultz MB, Zobel J, Holt KE, Bioinformatics 31:3350–3352, 2015,

813 <https://doi.org/10.1093/bioinformatics/btv383>). **(G)** Mapping of paired-end reads to *las* BGC_v2.
814 Contigs in green boxes represent the *las* BGC, red boxes represent the 5' end of *las* BGC and
815 blue boxes represent the 3' end of *las* BGC. Panels D, E, G, and H were edited for clarity by
816 removing contigs which had either very few paired-end read connections, were mapping to
817 themselves or were very small. **(H)** BGC distribution in Forcepia_v2 sp. Metagenome.
818 AntiSMASH (Blin K, Shaw S, Steinke K, Villebro R, Ziemert N, Lee SY, Medema MH, Weber
819 T, Nucleic Acid Res 47:W81–W87, 2019, <https://doi.org/10.1093/nar/gkz310>) annotations of
820 bacterial contigs greater than 3000bp are shown. Each bar indicates a MAG, grouped by phylum.
821 The star represents the MAG containing the *las* BGC. BGC annotations have been simplified
822 into polyketide synthase (PKS), Type 1 PKS, Type 3 PKS, *trans*-AT PKS, nonribosomal peptide
823 synthetase (NRPS), ribosomally synthesized, post-translationally modified peptide (RiPP), hgIE-
824 KS, hgIE-KS-T1PKS, terpenes, and others. **(I)** Phylogenetic tree of 51 different Verrucomicrobia
825 genomes. Bootstrap values were calculated using RaxML with 1000 bootstrap replicates.

826 **Fig S2.** Clades from a phylogenetic tree of 944 KS domains from *trans*-AT PKS and the
827 erythromycin BGC as an outgroup, containing KS domains from the *las* BGC. Color within the
828 individual clades corresponds to the chemical structure shown on its right. 'i' and 'c' in *lasD*
829 KS1 indicate the incomplete and complete KS domain in *lasD* respectively.

830 **Fig S3.** **(A)** Alignment of *las* AT and AH domains with AT and AH domains from different
831 *trans*-AT PKS pathways. Active sites as well as sites distinguishing AT and AH domains (Jenner
832 M, Afonso JP, Kohlhaas C, Karbaum P, Frank S, Piel J, Oldham NJ, Chem Commun 52:5262–
833 5265, 2016, <https://doi.org/10.1039/C6CC01453D>) have been marked. **(B)** Phylogenetic tree of
834 AT and AH domains. The different types of domain separate into different clades (Jenner M,
835 Afonso JP, Kohlhaas C, Karbaum P, Frank S, Piel J, Oldham NJ, Chem Commun 52:5262–5265,

836 2016, <https://doi.org/10.1039/C6CC01453D>). (C) Phylogenetic tree of ECH1 and ECH2
837 domains. Both the domains separate into different clades (Slocum ST, Lowell AN, Tripathi A,
838 Shende VV, Smith JL, Sherman DH, Methods Enzymol 604:207–236, 2018,
839 <https://doi.org/10.1016/bs.mie.2018.01.034>). (D-E) Alignment of *las* (D) ECH1 and (E) ECH2
840 domains with respective ECH domains from other PKS pathways. Sequence that is required for
841 the formation of the oxyanion hole which stabilizes the enolate anions is marked. LasH_a and
842 LasO_a are proposed to be inactive as they are truncated and show poor homology to the rest of
843 the ECH domains (Gu L, Jia J, Liu H, Håkansson K, Gerwick WH, Sherman DH, J Am Chem
844 Soc 128:9014–9015, 2006, <http://doi.org/10.1021/ja0626382>, Matilla MA, Stöckmann H, Leeper
845 FJ, Salmond GPC, J Biol Chem 287:39125–39138, 2012,
846 <https://doi.org/10.1074/jbc.M112.401026>). (F) Alignment of *las* KS domains with active site
847 (CHH) marked. ‘i’ and ‘c’ in the LasD KS indicate the incomplete and complete KS domain in
848 different repeats of LasD respectively. LasD is a decarboxylating KS which are known to lack
849 the active site cysteine (Walker PD, Weir ANM, Willis CL, Crump MP, Nat Prod Rep 38:723–
850 756, 2021, <https://doi.org/10.1039/D0NP00045K>). (G) Alignment of *las* KR domains with two
851 from the erythromycin BGC to allow comparison. Active site residues and conserved motifs are
852 marked. The presence or absence of the second aspartate in the LDD motif is supposed to predict
853 the stereochemistry of the hydroxyl group (Keatinge-Clay AT, Chem Biol 14:898–908, 2007,
854 <https://doi.org/10.1016/j.chembiol.2007.07.009>, Caffrey P, ChemBioChem 4:654–657, 2003,
855 <https://doi.org/10.1002/cbic.200300581>). Figures have been truncated for clarity and to show
856 only the relevant sites. In phylogenetic trees, *las* BGC domains are highlighted in white.

857 **Fig S4.** (A) Phylogenetic tree of DH and PS domains, which separate into different clades
858 (Wagner DT, Zhang Z, Meoded RA, Cepeda AJ, Piel J, Keatinge-Clay AT, ACS Chem Biol

859 13:975–983, 2018, <http://doi.org/10.1021/acscchembio.8b00049>). *Las* BGC DH/PS domains are
860 highlighted in white. **(B)** Alignment of PS domains identified in the *las* BGC with PS domains
861 from other *trans*-AT PKS pathways. The DH domain from the erythromycin BGC is used for
862 comparison. LasO DH2 and LasM DH4 are annotated as putative PS domains. Generally, PS
863 domains have a Hx₄P motif instead of a Hx₈P and they lack the catalytic aspartate at the
864 DxxxQ/H motif (Wagner DT, Zhang Z, Meoded RA, Cepeda AJ, Piel J, Keatinge-Clay AT, ACS
865 Chem Biol 13:975–983, 2018, <http://doi.org/10.1021/acscchembio.8b00049>, Pöplau P, Frank S,
866 Morinaka BI, Piel J, Angew Chem Int Ed Engl 52:13215–13218, 2013,
867 <https://doi.org/10.1002/anie.201307406>). This was found to be true only for LasM DH4 and not
868 LasO DH2. However, identical variations from a traditional PS domain architecture are also seen
869 in PS domains found in the mandelalide pathway (MndC DH3 and MndD DH3) (Lopera J,
870 Miller IJ, McPhail KL, Kwan JC, mSystems 2:e00096–17, 2017,
871 <https://doi.org/10.1128/mSystems.00096-17>). **(C)** Alignment of double bond-shifting DH
872 domains identified in *las* BGC with similar domains found in other *trans*-AT PKS pathways. The
873 DH domain from the erythromycin BGC is used for comparison. LasM DH1 and LasN DH1 are
874 annotated as putative double bond-shifting DH domains. Generally, in DH shifting domains the
875 conserved proline (P) in Hx₃P motif is often replaced by either valine (V) or leucine (L). In the
876 case of LasM DH1, a methionine (M) instead of V or L appears in the place of P, which is in line
877 with what is observed in difficidin biosynthesis as well (Chen X-H, Vater J, Piel J, Franke P,
878 Scholz R, Schneider K, Koumoutsis A, Hitzeroth G, Grammel N, Strittmatter AW, Gottschalk G,
879 Süssmuth RD, Borriss R, J Bacteriol 188:4024–4036, 2006, [https://doi.org/10.1128/JB.00052-](https://doi.org/10.1128/JB.00052-06)
880 [06](https://doi.org/10.1128/JB.00052-06)). Furthermore, DH shifting domains are sometimes characterized by the replacement of the
881 conserved aspartic acid (D) with asparagine (N) and substitution of glutamine (Q) or histidine

882 (H) with V or L in the DxxxQ/H motif. Even though LasN DH1 has an N in place of D in the
883 DxxxQ/H motif, it substitutes Q/H with a serine (S). This is unusual and not found in any other
884 double bond shifting DH. **(D)** Alignment of DH domains present in the *las* BGC with the DH
885 domain from the erythromycin BGC. Putative PS and double bond-shifting DH domains have
886 been excluded. LasH DH1 and LasM DH2 are annotated as inactive domains due to disrupted
887 catalytic motifs Hx₈P and DxxxQ/H. Even though in LasL DH1 the catalytic aspartic acid is
888 replaced by glutamic acid (DxxxQ/H motif), we propose it is active, as a similar mutation is
889 observed in the palmerolide BGC (Avalon NE, Murray AE, Daligault HE, Lo C-C, Davenport
890 KW, Dichosa AEK, Chain PSG, Baker BJ, *Front Chem* 9, 2021,
891 <https://doi.org/10.3389/fchem.2021.802574>). **(E)** Alignment of LasL DH3 with other DH domains
892 having a serine in place of proline in Hx₈P motif. The DH domain from the erythromycin BGC is
893 used for comparison. Sequence headers in blue represent DH domains annotated as active while
894 in red represent the ones annotated as inactive.

895 **Fig S5.** **(A)** 2D visualization of the initial Autometa binning of Forcepia_v2. The “*Ca. T.*
896 *lasonolidus*” genome is circled in black and contigs making up the *las* BGC are marked with
897 arrows. Axes represent dimension-reduced Barnes-Hut Stochastic Neighbor Embedding (BH-
898 tSNE) values (BH-tSNE x and BH-tSNE y). **(B)** 3D visualization of contigs present in the “*Ca.*
899 *T. lasonolidus*” genome. Contigs making up the *las* BGC are colored red. **(C)** GC percentage of
900 different sets of genes in Forcepia_v2 “*Ca. T. lasonolidus*”. *Las* BGC genes are colored in red.
901 **(D)** and **(E)** Codon adaptation index (CAI) of different categories of genes present in
902 Forcepia_v1 “*Ca. T. lasonolidus*” and Forcepia_v2 “*Ca. T. lasonolidus*”, respectively. *Las* BGC
903 genes are colored in red. P values for pairwise comparison between different categories of genes
904 are shown in the matrix below their respective plots. Values with $p < 0.05$ are considered

905 significant. Other non-significant p values are colored red. Annotated and hypothetical genes
906 represent the genes annotated with a function and genes annotated as hypothetical respectively
907 by Prokka (Seemann T, Bioinformatics 30:2068–2069, 2014,
908 <https://doi.org/10.1093/bioinformatics/btu153>).

909 **Table S1.** List of oligonucleotide primers used for different purposes. **(A)** Primers used for
910 screening the *Forcepia* sp. fosmid library before WGS. **(B)** Primers used for screening the
911 *Forcepia* sp. fosmid library after WGS. **(C)** Primers used for confirming the presence of terminal
912 connections with the *las* BGC.

913 **Table S2.** Metadata and taxonomic classification of all the MAGs

914 **Table S3.** Contigs making up the three repeats of the *las* BGC in “*Ca. T. lasonolidus*” in
915 Forcepia_v1 and Forcepia_v2. Contig IDs represent the labels in **Fig. 5** of the main text.

916 **Table S4.** Gene annotation in Forcepia_v1 and Forcepia_v2 “*Ca. T. lasonolidus*”. **(A)** Non-
917 pseudogenes annotated as Eukaryotic-like proteins. **(B)** Genes forming the PV BMC cluster. **(C)**
918 Non-pseudogenes annotated by dbCAN2

919 **Text S1.** Supplementary methods

920















